000301322 001__ 301322
000301322 005__ 20250516113146.0
000301322 0247_ $$2doi$$a10.3390/cancers17091513
000301322 0247_ $$2pmid$$apmid:40361440
000301322 037__ $$aDKFZ-2025-00994
000301322 041__ $$aEnglish
000301322 082__ $$a610
000301322 1001_ $$aManea, Selma$$b0
000301322 245__ $$aDICER1 Mutational Spectrum in Intracranial CNS-Neoplasias-A Review and a Report from the CNS-InterREST GPOH Study Center.
000301322 260__ $$aBasel$$bMDPI$$c2025
000301322 3367_ $$2DRIVER$$aarticle
000301322 3367_ $$2DataCite$$aOutput Types/Journal article
000301322 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747316936_1547$$xReview Article
000301322 3367_ $$2BibTeX$$aARTICLE
000301322 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301322 3367_ $$00$$2EndNote$$aJournal Article
000301322 520__ $$aDICER1 tumor predisposition syndrome is a genetic condition that increases the risk of developing certain cancer types. While thyroid tumors are the main tumors caused by this condition in adult oncology, children and adolescents with DICER1 germline mutations may suffer from a broader spectrum of tumors, including Sertoli-Leydig cell tumors, pleuropulmonary blastomas, embryonal rhabdomyosarcomas, and pineoblastomas. Although these diseases-many of which are hallmark tumors of DICER1 syndrome and rarely occur sporadically-have been known for several years, the more recent identification of DICER1 mutations in embryonal tumors with multilayered rosettes (ETMR) and DICER1-associated intra- and extracranial sarcomas has expanded the spectrum of tumor types potentially linked to DICER1 syndrome. This review sought to investigate the presence and characteristics of DICER1 mutations in rare CNS tumors and to discuss their potential implications for early recognition of DICER1-related syndromes. To address this, we conducted a comprehensive systematic literature review and analyzed data from our nationwide German database (CNS-InterREST) regarding these entities. When present, DICER1 mutation status, mutation type (somatic vs. germline), and localization within the gene were recorded. Demographic and clinical data-including age at diagnosis and tumor localization-were also evaluated where available. We found that the prevalence of DICER1 mutations in the cohort of ETMR patients included in the CNS-InterREST study was exceedingly low (1/31). The distribution of DICER1 mutations in patients with ETMR or intracranial sarcomas is comparable to that in other previously identified DICER1-mutant tumors. Our literature review demonstrates that within the 248 cases, which include three intracranial DICER1-mutated neoplasias and one reference group, most somatic mutations accumulate in the RNase IIIb domain, while germline mutations are usually evenly distributed throughout the gene. Overall, further research is necessary to unravel the cell-of-origin of the respective tumor types and whether other, hitherto undescribed, genetic factors may contribute to the development of ETMR and DICER1-associated intracranial sarcomas.
000301322 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000301322 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301322 650_7 $$2Other$$aDICER1
000301322 650_7 $$2Other$$aDICER1 syndrome
000301322 650_7 $$2Other$$apediatric cancer
000301322 650_7 $$2Other$$atumor predisposition syndrome
000301322 7001_ $$00000-0001-7488-6885$$aFincke, Victoria E$$b1
000301322 7001_ $$00000-0002-8237-1854$$aFrühwald, Michael C$$b2
000301322 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b3$$udkfz
000301322 7001_ $$avon Zezschwitz, Barbara$$b4
000301322 7001_ $$aJohann, Pascal D$$b5
000301322 7001_ $$aMucha, Marlena$$b6
000301322 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers17091513$$gVol. 17, no. 9, p. 1513 -$$n9$$p1513$$tCancers$$v17$$x2072-6694$$y2025
000301322 909CO $$ooai:inrepo02.dkfz.de:301322$$pVDB
000301322 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000301322 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000301322 9141_ $$y2025
000301322 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-14
000301322 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2024-12-14
000301322 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x0
000301322 980__ $$ajournal
000301322 980__ $$aVDB
000301322 980__ $$aI:(DE-He78)B360-20160331
000301322 980__ $$aUNRESTRICTED